213 related articles for article (PubMed ID: 27321026)
21. Normal and abnormal patterns of 18F-fluorodeoxyglucose PET/CT in lymphoma.
Bar-Shalom R
Radiol Clin North Am; 2007 Jul; 45(4):677-88, vi-vii. PubMed ID: 17706532
[TBL] [Abstract][Full Text] [Related]
22. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
23. Value of 18F-FDG PET and PET/CT for evaluation of pediatric malignancies.
Uslu L; Donig J; Link M; Rosenberg J; Quon A; Daldrup-Link HE
J Nucl Med; 2015 Feb; 56(2):274-86. PubMed ID: 25572088
[TBL] [Abstract][Full Text] [Related]
24. The role of FDG PET in the management of lymphoma: what is the evidence base?
Kirby AM; Mikhaeel NG
Nucl Med Commun; 2007 May; 28(5):335-54. PubMed ID: 17414883
[TBL] [Abstract][Full Text] [Related]
25. Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers.
Zukotynski KA; Kim CK
PET Clin; 2017 Oct; 12(4):393-405. PubMed ID: 28867111
[TBL] [Abstract][Full Text] [Related]
26. Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma.
Mylam KJ; Nielsen AL; Pedersen LM; Hutchings M
PET Clin; 2014 Oct; 9(4):443-55, vi. PubMed ID: 26050946
[TBL] [Abstract][Full Text] [Related]
27. (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes.
Wray R; Solnes L; Mena E; Meoded A; Subramaniam RM
PET Clin; 2015 Jul; 10(3):423-30. PubMed ID: 26099676
[TBL] [Abstract][Full Text] [Related]
28. Perspectives of molecular imaging and radioimmunotherapy in lymphoma.
Iagaru A; Goris ML; Gambhir SS
Radiol Clin North Am; 2008 Mar; 46(2):243-52, viii. PubMed ID: 18619379
[TBL] [Abstract][Full Text] [Related]
29. Clinical value of ¹⁸F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: a seven-case series and review of the literature.
Yamashita H; Kubota K; Takahashi Y; Minamimoto R; Morooka M; Kaneko H; Kano T; Mimori A
Mod Rheumatol; 2014 Jul; 24(4):645-50. PubMed ID: 24252024
[TBL] [Abstract][Full Text] [Related]
30. PET/computed tomography and lymphoma.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2013 Sep; 51(5):833-44. PubMed ID: 24010908
[TBL] [Abstract][Full Text] [Related]
31. Precision Medicine and PET-Computed Tomography in Pediatric Malignancies.
Sanli Y; Yilmaz E; Subramaniam RM
PET Clin; 2017 Oct; 12(4):423-435. PubMed ID: 28867113
[TBL] [Abstract][Full Text] [Related]
32. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma.
Okada M; Sato N; Ishii K; Matsumura K; Hosono M; Murakami T
Radiographics; 2010; 30(4):939-57. PubMed ID: 20631361
[TBL] [Abstract][Full Text] [Related]
33. PET imaging in lymphoma.
Hutchings M
Expert Rev Hematol; 2009 Jun; 2(3):261-76. PubMed ID: 21082968
[TBL] [Abstract][Full Text] [Related]
34. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients.
Abdulqadhr G; Molin D; Aström G; Suurküla M; Johansson L; Hagberg H; Ahlström H
Acta Radiol; 2011 Mar; 52(2):173-80. PubMed ID: 21498346
[TBL] [Abstract][Full Text] [Related]
35. PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.
Basu S; Alavi A
PET Clin; 2016 Jul; 11(3):203-7. PubMed ID: 27321025
[TBL] [Abstract][Full Text] [Related]
36. Role of positron emission tomography in urological oncology.
Rioja J; Rodríguez-Fraile M; Lima-Favaretto R; Rincón-Mayans A; Peñuelas-Sánchez I; Zudaire-Bergera JJ; Parra RO
BJU Int; 2010 Dec; 106(11):1578-93. PubMed ID: 21078036
[TBL] [Abstract][Full Text] [Related]
37. Are we ready for positron emission tomography/computed tomography-based target volume definition in lymphoma radiation therapy?
Yeoh KW; Mikhaeel NG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):14-20. PubMed ID: 22578540
[TBL] [Abstract][Full Text] [Related]
38. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.
Barrington SF; Mikhaeel NG; Kostakoglu L; Meignan M; Hutchings M; Müeller SP; Schwartz LH; Zucca E; Fisher RI; Trotman J; Hoekstra OS; Hicks RJ; O'Doherty MJ; Hustinx R; Biggi A; Cheson BD
J Clin Oncol; 2014 Sep; 32(27):3048-58. PubMed ID: 25113771
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of staging and early response to chemotherapy with whole-body diffusion-weighted MRI in malignant lymphoma patients: A comparison with FDG-PET/CT.
Tsuji K; Kishi S; Tsuchida T; Yamauchi T; Ikegaya S; Urasaki Y; Fujiwara Y; Ueda T; Okazawa H; Kimura H
J Magn Reson Imaging; 2015 Jun; 41(6):1601-7. PubMed ID: 25111444
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma.
Pinilla I; Gómez-León N; Del Campo-Del Val L; Hernandez-Maraver D; Rodríguez-Vigil B; Jover-Díaz R; Coya J
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):567-75. PubMed ID: 21150860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]